Orexo and SVF Vaccines Partner on AmorphOX-Based LNP-mRNA Vaccine Research in Sweden
Orexo and SVF Vaccines collaborate to explore AmorphOX® powder formulation of LNP-mRNA vaccines, aiming to improve stability, storage, and needle-free intr
Research Desk
Orexo AB (publ.) (STO: ORX) (OTCQX: ORXOY) and SVF Vaccines AB have announced a research collaboration to investigate whether Orexo's proprietary powder-based drug delivery technology, AmorphOX, can be used to develop stable powder-based formulations of lipid nanoparticle (LNP)-encapsulated messenger RNA (mRNA) vaccines.
Orexo and SVF Vaccines Evaluate AmorphOX for LNP-mRNA Formulations
The collaboration will assess whether LNP-mRNA formulations can be formulated and spray dried using AmorphOX while preserving critical nanoparticle properties and functional mRNA activity.
The project combines Orexo's expertise in powder formulation and intranasal drug delivery with SVF Vaccines' expertise in vaccine development.
Addressing Stability Challenges in mRNA Vaccines
According to the companies, lipid nanoparticles protect mRNA and enable its delivery into cells. However, maintaining the stability of both the mRNA and its lipid carrier presents formulation challenges that can complicate storage and distribution.
LNP-mRNA formulations often require cold-chain storage and transportation, and stable powder-based formulations could reduce these requirements, simplify handling and distribution, and help broaden access to future mRNA-based products.
If successful, the initial program could support further development of powder-based mRNA vaccines with improved storage, distribution and handling characteristics, including potential needle-free intranasal applications.
The companies noted that further development toward intranasal administration would require additional evaluation of delivery performance, tolerability, and mucosal immune responses.
Statements from Both Companies
"This collaboration will explore whether AmorphOX can address an important formulation challenge in mRNA vaccine development," said Nikolaj Sørensen, President and CEO at Orexo AB. "Our initial objective is to establish whether we can develop stable powder-based formulations while preserving LNP integrity and mRNA activity. Positive results would provide a foundation for further development and help us assess the potential of our technology in vaccines and other biologic applications."
Matti Sällberg, Founder and Chief Scientific Officer of SVF Vaccines, commented, "The clinical success of mRNA vaccines has highlighted both the enormous promise and the formulation challenges associated with these technologies. The ability to convert LNP-mRNA formulations into a stable dry powder suitable for nasal administration could represent an important advancement for the field. Intranasal vaccination offers an opportunity to generate immunity where respiratory pathogens enter the body. This collaboration is an important first step toward exploring how our mRNA vaccine expertise and Orexo's formulation capabilities could support that goal."
Part of Orexo's Broader AmorphOX Strategy
The collaboration forms part of Orexo's strategy to evaluate AmorphOX across additional therapeutic areas and molecule classes.
Results from the initial feasibility program will inform decisions on subsequent development and potential expansion of the collaboration.
Background on the Technology and the Companies
Messenger RNA carries instructions that cells use to produce proteins.
In vaccines, mRNA instructs cells to produce an antigen that helps the immune system recognize and respond to a specific pathogen. Lipid nanoparticles are tiny particles made from lipids that protect mRNA from degradation and facilitate its delivery into cells, making them a key component of mRNA vaccines and therapeutics.
SVF Vaccines is a clinical-stage biotechnology company focused on the discovery and development of innovative vaccines and immunotherapies targeting serious viral infections.
The company's pipeline is built on proprietary antigen design strategies that aim to induce both potent neutralizing antibody responses and durable T-cell immunity, supported by expertise in immunology, virology, and translational medicine.
Orexo is a Swedish pharmaceutical company dedicated to advancing treatments for severe diseases and life-saving rescue medications. At the core of its innovation is AmorphOX, a proprietary drug delivery technology that improves bioavailability and stability for both large and small molecules.
With over 30 years of experience and multiple drugs approved globally, Orexo is advancing a diversified pipeline of programs in clinical and preclinical development. The company is headquartered in Uppsala, Sweden, is listed on Nasdaq Stockholm's main market, and trades as ADRs on the OTCQX market in the United States.
Tracked in the database
Pharmaceutical Plant Projects · Europe
Pharmaceutical Plant Projects
Europe
Chemical
11 November 2026
3 min read
Tagged
Also read
ESTEVE CDMO Commits Over $80 Million to New 250 m³ Manufacturing Site in Shaoxing, China
Millicent Pharma Invests Millions in Larne Manufacturing Expansion, Creating 20 Jobs in UK
Orion Pharma Invests Over $112 Million to Upgrade Four Finland Manufacturing Sites
Live from the tracker
The projects behind these stories
Capacity, capex, stage, contractors and verified contacts for every project we track, updated daily.